Physically active patients with type 1 diabetes (T1D) face a very specific challenge in their management of glycaemia: physical activity can dramatically alter glucose homeostasis both acutely and over a period of several hours. The magnitude of this behaviorally triggered physiological disturbance is highly variable and depends on a number of factors such as insulin- on-board, prandial state, and fitness to name only a few. These complex interactions and associated fear of hypoglycemia often lead to avoidance of physical activity. We propose to address this specific hurdle of living with diabetes by empowering patients through a network of medical devices, assembled into an adaptive artificial pancreas (AP) platform, tailored to the needs and choices of each patient. This project unites two leading groups in artificial pancreas development, the University of Virginia Center for Diabetes Technology and the Illinois Institute of Technology Center for Diabetes Research and Education. We propose to leverage our extensive technology portfolio in AP platform, closed loop algorithms, exercise detection and quantification, and modelling to address the following specific aims: 1. Patient-specific exercise risk alert system informing patients at the onset of exercise of likely hypoglycemia based on: (i) tuning a risk detector to each patient using DiAs cloud functionalities, and (ii) personalized simulation-based advice on treatment adaptation. 2. Exercise-informed automated insulin dosing: Upgrade to AP control system using exercise sensing to track metabolic risk and adjust insulin to maintain safe BG levels. 3. Fully-integrated Exercise-adapted AP system: We hypothesize that an exercise-informed AP system with both feed-forward (1) and feedback (2) components, freeing the patient from obligatory additional devices will improve glycemic safety and technology acceptance. We will demonstrate feasibility, safety, and efficacy of each of the proposed modules, independently and in concert, through three human clinical trials: two short term inpatient demonstration trials and one final longer term (4 months) home trial. This final trial will also explore psychosocial aspects of exercising with our platform, and start addressing key aspects of safety, accounting for adherence and technology acceptance of such a complex system. We expect the proposed system to enhance the safety and efficacy of AP in real life conditions. By creating a novel data infrastructure and optimal exercise control algorithms, this project has also the potential to generate clinically relevant derivatives for other mode of treatment.

Public Health Relevance

The basic philosophy behind this project is simple: by using a hierarchical modular architecture, the exercise-informed Artificial Pancreas system is capable to adjust it functionalities to available devices and therefore can ensure optimal glycemic safety accounting for patients' device choices. As we escalate the use of devices (AP enabled platform, exercise sensors), new functionalities become available (closed loop glucose control, exercise-informed control), reducing hypoglycemic risk at different times around exercise: for example adding an exercise sensor to a sensor augmented pump (SAP) system limits the exposure to hypoglycemia during exercise (SAPEX), while enabling closed loop control limits hypoglycemia the night afterward (AP). This escalation culminates with an exercise-informed artificial pancreas system that combines the patient specific alert and advice system with AP technologies including exercise specific feedback control modules (APEX). We will demonstrate safety and efficacy of all these glucose control modes in three human clinical trials: two safety and feasibility studies of an exercise-informed decision support system and an exercise-informed automatic insulin modulation system respectively; and finally a long term (4 months) study where we will explore the efficacy of each AP mode.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Type 1 Diabetes Targeted Research Award (DP3)
Project #
1DP3DK106826-01
Application #
8971447
Study Section
Special Emphasis Panel (ZDK1-GRB-9 (M2))
Program Officer
Arreaza-Rubin, Guillermo
Project Start
2015-08-01
Project End
2019-07-31
Budget Start
2015-08-01
Budget End
2019-07-31
Support Year
1
Fiscal Year
2015
Total Cost
$2,979,886
Indirect Cost
$926,596
Name
University of Virginia
Department
Psychiatry
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Breton, Marc D; Cherñavvsky, Daniel R; Forlenza, Gregory P et al. (2017) Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study. Diabetes Care 40:1644-1650
Breton, Marc D (2017) Handling Exercise During Closed Loop Control. Diabetes Technol Ther 19:328-330